A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity
← catalyst calendarNCT06577766 · readout in 418 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
63actual
Sites
4
Countries
Netherlands, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-03 | actual | When the study began enrolling |
| Primary completion | 2027-10-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: NNC0638-0355
- Drug: Placebo (NNC0638-0355)
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of treatment emergent adverse events (TEAE)
measured From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks)
Part B,C,D and E : Number of treatment emergent adverse events (TEAE)
measured From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed